Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Naik HB, Pichard DC, Schwartz DM, O'Brien M, Masciocchi M, Thompson J, Sen HN, Steinberg SM, Mitchell SA, de Jesus AA, McCalmont TH, Dey A, Rosenstein RK, Deng Z, Goldbach-Mansky R, Mehta NN, Cowen EW

Publication

Journal of the American Academy of Dermatology

Publication ID (Profile URL)

https://researcherprofiles.org/profile/366100725

Publication Year

2022

PubMed ID

36116584

Publication Title

Naik HB, Pichard DC, Schwartz DM, O'Brien M, Masciocchi M, Thompson J, Sen HN, Steinberg SM, Mitchell SA, de Jesus AA, McCalmont TH, Dey A, Rosenstein RK, Deng Z, Goldbach-Mansky R, Mehta NN, Cowen EW. Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial. J Am Acad Dermatol. 2022 Dec; 87(6):1380-1383.